+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report By Therapeutic Area, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 5893184
The global pharmacogenomics technology market size is expected to reach USD 12.3 billion by 2030, expanding at a CAGR of 8.7% from 2023 to 2030. Diagnostics is coming to grips with the wave of pharmacogenomic tests that are followed by new biological therapy introductions. These tests enable cost-effective treatment and also add value to the process of drug development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to a significant source of progress in this pharmacogenomics companion diagnostics market.

In addition, pharmacogenomics testing products aid physicians in individualizing and optimization of the patient’s therapeutic regimen. Pharmacogenomics and theranostics are paving the way for integrated medicine. Rapid evolution in this group of specialized molecular diagnostic tests is contributing to improvement for the assessment of real-time treatment of disease.

However, the presence of challenges pertaining to early integration of pharmacogenomic based testing into drug development timelines for gaining the approval simultaneously is anticipated to impede growth. Proper designing and implementation of clinical trials in order to identify individual as well as population variations from a given therapy have become a necessary attribute for the success of theranostics.

Pharmacogenomics Technology Market Report Highlights

  • Oncology is estimated to account for the largest revenue share owing to the presence of a substantial number of products in this segment
  • Furthermore, precision oncology investigators envision in giving multiple medications, in varied sorts of combinations, in an effort to squelch a tumor rather than just temper its growth
  • Aforementioned fact is responsible for the estimated revenue share of cancer in the pharmacogenomics technology market
  • Polymerase Chain Reaction (PCR) was the largest revenue grossing segment of the with respect to technology for theranostics
  • Advantages associated with the use of the PCR technique makes it the current workhorse of clinical diagnostics
  • Moreover, reproducible and precise results produced with the assays without sacrificing the sensitivity are responsible for the estimated share
  • North American region dominates the pharmacogenomics technology market as a consequence of economic incentives for drug developers to pair their products with diagnostics.
  • Asia Pacific market is projected to showcase the fastest growth over the forecast period as the companies are engaged in capturing untapped opportunities
  • Key players operating include F Hoffman La Roche, Agilent Technologies, Thermo Fisher Scientific Inc., GE Healthcare, Pfizer, Qiagen NV, Leica Biosystems Nussloch GmBH, and Foundation Medicine.
  • Diagnostic companies are positioning themselves to offer theranostic tools by widening the application of in-vitro diagnostic technologies to include more than just disease detection


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Therapeutic area
1.1.2. Technology
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Therapeutic area outlook
2.2.2. Technology outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Pharmacogenomics Technology Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Pharmacogenomics Technology Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis
4.1. Pharmacogenomics Technology Market: Key Takeaways
4.2. Pharmacogenomics Technology Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Oncology
4.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1. Lung cancer
4.3.1.1.1. Lung cancer market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.2. Breast cancer
4.3.1.2.1. Breast cancer market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.3. Colorectal cancer
4.3.1.3.1. Colorectal cancer market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.4. Cervical cancer
4.3.1.4.1. Cervical cancer market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.5. Others
4.3.1.5.1. Others cancer market estimates and forecast 2018 to 2030 (USD Million)
4.4. Neurological Disorders
4.4.1. Neurological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Cardiovascular Disease
4.5.1. Cardiovascular disease market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Immunological Disorders
4.6.1. Immunological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Infectious Disease
4.7.1. Infectious disease market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Pharmacogenomics Technology: Technology Estimates & Trend Analysis
5.1. Pharmacogenomics Technology Market: Key Takeaways
5.2. Pharmacogenomics Technology Market: Movement & Market Share Analysis, 2022 & 2030
5.3. PCR
5.3.1. PCR market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. In-situ Hybridization
5.4.1. In-situ hybridization market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Immunohistochemistry
5.5.1. Immunohistochemistry market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Sequencing
5.6.1. Sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Pharmacogenomics Technology Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Pharmacogenomics Technology Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. QIAGEN
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. GE HealthCare
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Agilent Technologies, Inc.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. F. Hoffmann-La Roche Ltd.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. FOUNDATION MEDICINE, INC.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Thermo Fisher Scientific Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Leica Biosystems Nussloch GmBH
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Pfizer Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America pharmacList of Tablogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 3 North America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 4 North America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 6 U.S. pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 7 Canada pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 8 Canada pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 9 Europe pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 10 Europe pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 11 Europe pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 12 Germany pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 13 Germany pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 14 UK pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 15 UK pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 16 France pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 17 France pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 18 Italy pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 19 Italy pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 20 Spain pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 21 Spain pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 22 Sweden pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 23 Sweden pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 24 Norway pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 25 Norway pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 26 Denmark pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 27 Denmark pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 28 Asia Pacific pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 29 Asia Pacific pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 30 Asia Pacific pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 31 China pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 32 China pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 33 Japan pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 34 Japan pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 35 India pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 36 India pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 37 Australia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 38 Australia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 39 Thailand pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 40 Thailand pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 41 South Korea pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 42 South Korea pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 43 Australia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 44 Australia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 45 Latin America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 46 Latin America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 47 Latin America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 48 Brazil pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 49 Brazil pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 50 Mexico pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 51 Mexico pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 52 Argentina pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 53 Argentina pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 55 Middle East and Africa pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 56 Middle East and Africa pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 57 South Africa pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 58 South Africa pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 60 Saudi Arabia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 61 UAE pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 62 UAE pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 63 Kuwait pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 64 Kuwait pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Pharmacogenomics technology: Market outlook
Fig. 9 Pharmacogenomics technology: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Pharmacogenomics technology market driver impact
Fig. 15 Pharmacogenomics technology market restraint impact
Fig. 16 Pharmacogenomics technology market strategic initiatives analysis
Fig. 17 Pharmacogenomics technology market: Therapeutic area movement analysis
Fig. 18 Pharmacogenomics technology market: Therapeutic area outlook and key takeaways
Fig. 19 Oncology market estimates and forecasts, 2018 - 2030
Fig. 20 Neurological disorders market estimates and forecasts, 2018 - 2030
Fig. 21 Cardiovascular diseases market estimates and forecasts, 2018 - 2030
Fig. 22 Immunological disorders market estimates and forecasts, 2018 - 2030
Fig. 23 Infectious diseases market estimates and forecasts, 2018 - 2030
Fig. 24 Others market estimates and forecasts, 2018 - 2030
Fig. 25 Pharmacogenomics technology market: Technology movement analysis
Fig. 26 Pharmacogenomics technology market: Technology outlook and key takeaways
Fig. 27 PCR market estimates and forecasts, 2018 - 2030
Fig. 28 In-situ hybridization delivery market estimates and forecasts, 2018 - 2030
Fig. 29 Immunohistochemistry market estimates and forecasts, 2018 - 2030
Fig. 30 Sequencing market estimates and forecasts, 2018 - 2030
Fig. 31 Others market estimates and forecasts, 2018 - 2030
Fig. 32 Global Pharmacogenomics technology market: Regional movement analysis
Fig. 33 Global Pharmacogenomics technology market: Regional outlook and key takeaways
Fig. 34 North America market estimates and forecasts, 2018 - 2030
Fig. 35 U.S. market estimates and forecasts, 2018 - 2030
Fig. 36 Canada market estimates and forecasts, 2018 - 2030
Fig. 37 Europe. market estimates and forecasts, 2018 - 2030
Fig. 38 UK market estimates and forecasts, 2018 - 2030
Fig. 39 Germany market estimates and forecasts, 2018 - 2030
Fig. 40 France market estimates and forecasts, 2018 - 2030
Fig. 41 Italy market estimates and forecasts, 2018 - 2030
Fig. 42 Spain market estimates and forecasts, 2018 - 2030
Fig. 43 Sweden market estimates and forecasts, 2018 - 2030
Fig. 44 Norway market estimates and forecasts, 2018 - 2030
Fig. 45 Denmark market estimates and forecasts, 2018 - 2030
Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 47 Japan market estimates and forecasts, 2018 - 2030
Fig. 48 China market estimates and forecasts, 2018 - 2030
Fig. 49 India market estimates and forecasts, 2018 - 2030
Fig. 50 Australia market estimates and forecasts, 2018 - 2030
Fig. 51 Thailand market estimates and forecasts, 2018 - 2030
Fig. 52 South Korea market estimates and forecasts, 2018 - 2030
Fig. 53 Latin America market estimates and forecasts, 2018 - 2030
Fig. 54 Brazil market estimates and forecasts, 2018 - 2030
Fig. 55 Mexico market estimates and forecasts, 2018 - 2030
Fig. 56 Argentina market estimates and forecasts, 2018 - 2030
Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030
Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
Fig. 60 UAE market estimates and forecasts, 2018 - 2030
Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030

Companies Mentioned

  • QIAGEN
  • GE HealthCare
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • FOUNDATION MEDICINE, INC.
  • Thermo Fisher Scientific Inc.
  • Leica Biosystems Nussloch GmBH
  • Pfizer Inc.

Methodology

Loading
LOADING...

Table Information